Type 2 Diabetes Market Report 2026

Type 2 Diabetes Market Overview

• Type 2 Diabetes market size has reached to $51.47 billion in 2025 • Expected to grow to $78.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.1% • Growth Driver: Elevated Rates Of Obesity And Heart Disease Fuel Expansion Of The Type 2 Diabetes Market • Market Trend: Innovative Products Like Mounjaro Revolutionize The Type 2 Diabetes Market For Enhanced Patient Care • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Type 2 Diabetes Market?

Type 2 diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels due to insulin resistance and inadequate insulin production. The development of Type 2 diabetes is influenced by a combination of genetic, lifestyle and environmental factors. Dietary and pharmaceutical adjustments can manage type 2 diabetes by lowering weight, eating a healthy diet and exercising consistently. The main types of drug classes in type 2 diabetes are dipeptidyl peptide-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas and other insulin secretagogues, biguanides, sodiumglucose cotransporter 2 inhibitors and others. Dipeptidyl peptidase-4 (DPP-4) inhibitors refer to a class of oral medications that work by blocking the enzyme responsible for breaking down incretin hormones, which help regulate blood sugar levels. They are used for several applications, including glycemic control, cardiovascular safety, hypoglycemia avoidance and others by targeting various end-users, such as children and adults.

What Is The Type 2 Diabetes Market Growth Forecast?

The type 2 diabetes market size is expected to see strong growth in the next few years. It will grow to $78.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing demand for weight-management focused therapies, rising adoption of personalized diabetes treatment plans, expansion of digital therapeutic platforms, growing focus on preventive diabetes management, increasing investments in next-generation antidiabetic drugs. Major trends in the forecast period include increasing adoption of glp-1 receptor agonists, rising focus on cardiometabolic risk management, growing use of combination drug therapies, expansion of lifestyle-integrated treatment approaches, enhanced emphasis on long-term glycemic control.

Global Type 2 Diabetes Market Segmentation

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes 2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications 3) By End-User: Children, Adults Subsegments: 1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin 2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide 3) By Thiazolidinediones: Pioglitazone, Rosiglitazone 4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol 5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide 6) By Biguanides: Metformin, Buformin, Phenformin 7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin 8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What Is The Driver Of The Type 2 Diabetes Market?

Increasing rates of obesity and heart disease are expected to propel the growth of the type 2 diabetes market going forward. Obesity is a medical condition where excess body fat has accumulated to an unhealthy level, while heart disease refers to a range of conditions that affect the heart and blood vessels. Excess body weight increases the risk of insulin resistance, leading to high blood sugar levels and the development of type 2 diabetes. In contrast, high blood sugar levels can damage blood vessels and nerves that control the heart and blood vessels, leading to heart disease. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were struggling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, rising rates of obesity and heart disease are driving the growth of the type 2 diabetes industry.

Key Players In The Global Type 2 Diabetes Market

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Global Type 2 Diabetes Market Trends and Insights

Major companies operating in the type 2 diabetes market are focusing on developing advanced solutions, such as extended-indication SGLT2/GLP-1 combination therapies, to deliver enhanced glycemic control, reduce comorbidities, and improve patient adherence. Extended-indication SGLT2/GLP-1 combination therapies refer to pharmaceutical regimens that combine sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to simultaneously target blood glucose regulation, obesity, cardiovascular and renal outcomes in patients with type 2 diabetes. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), expanding usage beyond adult populations and signalling a broader patient-base strategy. This innovation offers once-daily oral dosing in younger patients, integrated cardiometabolic and renal protection data, and market expansion into paediatric and early-stage type 2 diabetes segments, driving growth in the global type 2 diabetes market.

What Are Latest Mergers And Acquisitions In The Type 2 Diabetes Market?

In January 2024, Roche Group, a Switzerland-based healthcare company, acquired Carmot Therapeutics for an undisclosed amount. Roche obtains access to Carmot’s current R&D portfolio including all clinical and pre-clinical assets, as well as exclusive access to Carmot’s innovative Chemotype Evolution discovery platform in metabolism, further strengthening Roche’s R&D efforts and portfolio across cardiovascular and metabolic diseases. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on advancing life-changing therapeutics for people with obesity and diabetes.

Regional Outlook

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Type 2 Diabetes Market?

The type 2 diabetes market consists of revenues earned by entities by providing services such as blood sugar monitoring, diabetes education and support, bariatric surgery and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The type 2 diabetes market also includes sales of blood glucose meters, insulin pens, insulin syringes, insulin pumps, metformin and diabetic socks. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Type 2 Diabetes Market Report 2026?

The type 2 diabetes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the type 2 diabetes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.